Quick Answer
Moleculin Biotech, Inc. reported Net Income Loss of -$33.56 million for the year ending 2025.
- Moleculin Biotech, Inc. showed a decrease of -28.8% in Net Income Loss from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Moleculin Biotech, Inc.'s Net Income Loss has declined by 754.8%.
- Historical annual values: Fiscal year 2025: -$33.56 million | Fiscal year 2024: -$26.05 million | Fiscal year 2023: -$29.77 million | Fiscal year 2022: -$29.03 million | Fiscal year 2021: -$15.89 million | Fiscal year 2020: -$17.36 million | Fiscal year 2019: -$13.21 million | Fiscal year 2018: -$11.88 million | Fiscal year 2017: -$9.81 million | Fiscal year 2016: -$3.93 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: